Download PDF
Thromb Haemost 2013; 110(01): 04
DOI: 10.1160/TH13-05-0362
Invited Editorial Focus
Schattauer GmbH

Dabigatran has the upper hand on warfarin

Markus Bender
1   Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
› Author Affiliations
Further Information

Publication History

Received: 03 May 2013

Accepted: 03 May 2013

Publication Date:
30 November 2017 (online)

Also available at
   Permissions and Reprints

 

Editorial Focus on Sun et al. Thromb Haemost 2013; 110: 153-161.

Refers to:

Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemiaThromb Haemost 2013; 110(07): 153-161
DOI: 10.1160/TH12-12-0942

 

  • References

  • 1 Deedwania P, Huang G. An update on antithrombotic therapy in atrial fibrillation: The role of newer and emergent drugs. Rev Cardiovasc Med 2012; 13: 104.
    PubMedSearch in Google Scholar
  • 2 Connolly S, Ezekowitz M, Yusuf S. et al. Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedSearch in Google Scholar
  • 3 Watanabe M, Siddiqui F, Qureshi A. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care 2012; 16: 203-209.
    CrossrefPubMedSearch in Google Scholar
  • 4 Sun L, Zhou W, Ploen R. et al. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 2013; 110: 153-161.
    Thieme ConnectPubMedSearch in Google Scholar